The Experts below are selected from a list of 38181 Experts worldwide ranked by ideXlab platform
Kazuhiro Yasufuku - One of the best experts on this subject based on the ideXlab platform.
-
First Evaluation of the New Thin Convex Probe Endobronchial Ultrasound Scope: A Human Ex Vivo Lung Study.
The Annals of thoracic surgery, 2016Co-Authors: Priya Patel, Hironobu Wada, Kentaro Hirohashi, Tatsuya Kato, Hideki Ujiie, Jin Young Ahn, Daiyoon Lee, William R. Geddie, Kazuhiro YasufukuAbstract:Background Endobronchial ultrasonography (EBUS)-guided transbronchial Needle Aspiration allows for sampling of mediastinal lymph nodes. The external diameter, rigidity, and angulation of the convex probe EBUS renders limited accessibility. This study compares the accessibility and transbronchial Needle Aspiration capability of the prototype thin convex probe EBUS against the convex probe EBUS in human ex vivo lungs rejected for transplant. Methods The prototype thin convex probe EBUS (BF-Y0055; Olympus, Tokyo, Japan) with a thinner tip (5.9 mm), greater upward angle (170 degrees), and decreased forward oblique direction of view (20 degrees) was compared with the current convex probe EBUS (6.9-mm tip, 120 degrees, and 35 degrees, respectively). Accessibility and transbronchial Needle Aspiration capability was assessed in ex vivo human lungs declined for lung transplant. The distance of maximum reach and sustainable endoscopic limit were measured. Transbronchial Needle Aspiration capability was assessed using the prototype 25G Aspiration Needle in segmental lymph nodes. Results In all evaluated lungs (n = 5), the thin convex probe EBUS demonstrated greater reach and a higher success rate, averaging 22.1 mm greater maximum reach and 10.3 mm further endoscopic visibility range than convex probe EBUS, and could assess selectively almost all segmental bronchi (98% right, 91% left), demonstrating nearly twice the accessibility as the convex probe EBUS (48% right, 47% left). The prototype successfully enabled cytologic assessment of subsegmental lymph nodes with adequate quality using the dedicated 25G Aspiration Needle. Conclusions Thin convex probe EBUS has greater accessibility to peripheral airways in human lungs and is capable of sampling segmental lymph nodes using the Aspiration Needle. That will allow for more precise assessment of N1 nodes and, possibly, intrapulmonary lesions normally inaccessible to the conventional convex probe EBUS.
-
Assessment of the new thin convex probe endobronchial ultrasound bronchoscope and the dedicated Aspiration Needle: a preliminary study in the porcine lung.
Journal of bronchology & interventional pulmonology, 2015Co-Authors: Hironobu Wada, Kentaro Hirohashi, Takahiro Nakajima, Takashi Anayama, Tatsuya Kato, Alexandria Grindlay, Judy Mcconnell, Ichiro Yoshino, Kazuhiro YasufukuAbstract:BACKGROUND Endobronchial ultrasound-guided transbronchial Needle Aspiration (EBUS-TBNA) allows for accurate minimally invasive mediastinal lymph node staging of lung cancer. The current convex probe EBUS (CP-EBUS) has limitations in the access to certain N1 lymph nodes (lobar and segmental) because of its size. The aim of this study was to assess the new thin CP-EBUS (TCP-EBUS) and an Aspiration Needle for sampling of N1 lymph nodes in a porcine model. METHODS The prototype TCP-EBUS (BF-Y0046, Olympus Medical Systems Corp.) with a thinner tip (5.9 mm) and larger bending angle (170 degrees upward) was used. Accessibility, operability, and TBNA capability of the TCP-EBUS were assessed and compared with the current CP-EBUS using porcine lungs. The endoscopic visibility range and the maximum reach were evaluated at the left upper lobe bronchus, tracheobronchus, and right lower lobe bronchus. The prototype Aspiration Needle (Olympus Medical Systems Corp.) was used for EBUS-TBNA. RESULTS In all of the evaluated bronchi (n=9), the TCP-EBUS had a greater reach (14.7 mm in the endoscopic visibility range, 16.0 mm in the maximum reach) than the current CP-EBUS. The TCP-EBUS was able to visualize 1 to 3 distal bifurcations farther compared with the current CP-EBUS. Adequate lymph node sampling from lobar and segmental lymph nodes was possible using the Aspiration Needle. CONCLUSIONS The TCP-EBUS has improved accessibility to peripheral bronchi with excellent operability and is capable of sampling lobar and segmental lymph nodes using the dedicated Aspiration Needle.
-
comparison of 21 gauge and 22 gauge Aspiration Needle during endobronchial ultrasound guided transbronchial Needle Aspiration
Respirology, 2011Co-Authors: Takahiro Nakajima, Kazuhiro Yasufuku, Ryo Takahashi, Masato Shingyoji, Tetsushi Hirata, Makiko Itami, Yukiko Matsui, Meiji Itakura, Toshihiko Iizasa, Hideki KimuraAbstract:Background and objective: Endobronchial ultrasound-guided transbronchial Needle Aspiration (EBUS-TBNA) has typically been performed using the 22gauge (G) dedicated TBNA Needle. Recently a new 21G TBNA Needle has been introduced. The efficacy of using a larger gauge biopsy Needle during EBUS-TBNA has not been reported. The purpose of this study was to compare the diagnostic yield and utility of 21G and 22G Needles during EBUS-TBNA. Methods: EBUS-TBNA was performed using both 21G and 22G Needles. Cytological and histological findings were recorded for each samples obtained by an independent cytologist and pathologist. The cellularity and blood contamination were evaluated in the cytological samples. The quality of the histological core was evaluated by the amount of blood clots versus the actual tissue. Each factor was compared within two slides from the two different size Needles. The diagnostic yield and the differences of the cytology and histology were analysed. Results: The evaluation of 45 lesions by EBUS-TBNA revealed that tumour cells were equally detected by both 21G and 22G Needles. Two patients of adenocarcinoma were histologically diagnosed only by the 21G Needle. Although histological structure was better preserved in five lesions collected by the 21G Needle, there was more blood contamination with the 21G Needle (P < 0.0001). Conclusions: There were no differences in the diagnostic yield between the 21G and 22G Needles during EBUS-TBNA. The preserved histological structure of the samples obtained by the 21G Needle may be useful for the diagnosis of mediastinal and hilar adenopathy of unknown aetiology which may be a challenge with the 22G Needle.
Russell Broaddus - One of the best experts on this subject based on the ideXlab platform.
-
salvaging the supernatant next generation cytopathology for solid tumor mutation profiling
Modern Pathology, 2018Co-Authors: Sinchita Roychowdhuri, Meenakshi Mehrotra, Ana Maria Bolivar, Brette Hannigan, Stephanie Zalles, Wenrui Ye, Dzifa Y Duose, Rashmi Kanagalshamanna, Bedia A Barkoh, Russell BroaddusAbstract:With the expanding role of targeted therapy in patients with solid tumors, pathologists face the daunting task of having to maximize limited volume tissue obtained by fine Needle Aspiration for a variety of molecular tests. While most molecular studies on fine Needle Aspiration samples have been reported using cellular material, recent studies have shown that a substantial amount of DNA can be retrieved from the supernatant fluid of aspirate Needle rinses after cell pelleting for cytospin or cell block preparations. In routine clinical workflow, the supernatant is discarded; however this fluid may provide a complementary source of DNA for tumor mutational profiling. In this study, we evaluated the post-centrifuged supernatant from 25 malignant and 10 benign fine Needle Aspiration Needle rinses. The mean and median DNA yields from the supernatants were 445 ng and 176.4 ng (range, 15.1–2958 ng), respectively. Next generation sequencing using the Ion AmpliSeq Cancer Hotspot Panel v2 detected somatic mutations in all 25 malignant samples. No mutations were detected in any of the benign samples tested. When available, mutations detected in the supernatant fluid were compared to the next generation sequencing analysis performed on a prior or concurrent surgical specimen from the same patient and showed 100% concordance. In a subset of cases (n = 19) mutations in EGFR, KRAS, BRAF, PIK3CA, and NRAS were successfully confirmed by droplet digital PCR, providing an orthogonal platform for mutation analysis. In summary, in this study we show that post centrifuged supernatants from fine Needle Aspiration Needle rinses can provide a robust substrate for expanded mutation profiling by next generation sequencing, as well as hotspot mutation testing by droplet digital PCR. The ability to detect somatic mutations from otherwise discarded supernatant fluids offers the ability to triage and effectively utilize limited volume fine Needle Aspiration samples when multiple molecular tests are requested, without the need to re-biopsy for additional tissue samples.
-
salvaging the supernatant next generation cytopathology for solid tumor mutation profiling
Modern Pathology, 2018Co-Authors: Sinchita Roychowdhuri, Meenakshi Mehrotra, Ana Maria Bolivar, Brette Hannigan, Stephanie Zalles, Wenrui Ye, Dzifa Y Duose, Rashmi Kanagalshamanna, Bedia A Barkoh, Russell BroaddusAbstract:With the expanding role of targeted therapy in patients with solid tumors, pathologists face the daunting task of having to maximize limited volume tissue obtained by fine Needle Aspiration for a variety of molecular tests. While most molecular studies on fine Needle Aspiration samples have been reported using cellular material, recent studies have shown that a substantial amount of DNA can be retrieved from the supernatant fluid of aspirate Needle rinses after cell pelleting for cytospin or cell block preparations. In routine clinical workflow, the supernatant is discarded; however this fluid may provide a complementary source of DNA for tumor mutational profiling. In this study, we evaluated the post-centrifuged supernatant from 25 malignant and 10 benign fine Needle Aspiration Needle rinses. The mean and median DNA yields from the supernatants were 445 ng and 176.4 ng (range, 15.1–2958 ng), respectively. Next generation sequencing using the Ion AmpliSeq Cancer Hotspot Panel v2 detected somatic mutations in all 25 malignant samples. No mutations were detected in any of the benign samples tested. When available, mutations detected in the supernatant fluid were compared to the next generation sequencing analysis performed on a prior or concurrent surgical specimen from the same patient and showed 100% concordance. In a subset of cases (n = 19) mutations in EGFR, KRAS, BRAF, PIK3CA, and NRAS were successfully confirmed by droplet digital PCR, providing an orthogonal platform for mutation analysis. In summary, in this study we show that post centrifuged supernatants from fine Needle Aspiration Needle rinses can provide a robust substrate for expanded mutation profiling by next generation sequencing, as well as hotspot mutation testing by droplet digital PCR. The ability to detect somatic mutations from otherwise discarded supernatant fluids offers the ability to triage and effectively utilize limited volume fine Needle Aspiration samples when multiple molecular tests are requested, without the need to re-biopsy for additional tissue samples.
Priya Patel - One of the best experts on this subject based on the ideXlab platform.
-
flexible 19 gauge endobronchial ultrasound guided transbronchial Needle Aspiration Needle first experience
Respiration, 2017Co-Authors: Chung Chun Tyan, Priya Patel, Kasia Czarnecka, Daniela Gompelmann, Ralf Eberhardt, Marc Fortin, Paul Maceachern, Christopher A Hergott, Elaine Dumoulin, Alain TremblayAbstract:Background: Endobronchial ultrasound-guided transbronchial Needle Aspiration (EBUS-TBNA) is a well-established first-line invasive modality for mediastinal lymph
-
First Evaluation of the New Thin Convex Probe Endobronchial Ultrasound Scope: A Human Ex Vivo Lung Study.
The Annals of thoracic surgery, 2016Co-Authors: Priya Patel, Hironobu Wada, Kentaro Hirohashi, Tatsuya Kato, Hideki Ujiie, Jin Young Ahn, Daiyoon Lee, William R. Geddie, Kazuhiro YasufukuAbstract:Background Endobronchial ultrasonography (EBUS)-guided transbronchial Needle Aspiration allows for sampling of mediastinal lymph nodes. The external diameter, rigidity, and angulation of the convex probe EBUS renders limited accessibility. This study compares the accessibility and transbronchial Needle Aspiration capability of the prototype thin convex probe EBUS against the convex probe EBUS in human ex vivo lungs rejected for transplant. Methods The prototype thin convex probe EBUS (BF-Y0055; Olympus, Tokyo, Japan) with a thinner tip (5.9 mm), greater upward angle (170 degrees), and decreased forward oblique direction of view (20 degrees) was compared with the current convex probe EBUS (6.9-mm tip, 120 degrees, and 35 degrees, respectively). Accessibility and transbronchial Needle Aspiration capability was assessed in ex vivo human lungs declined for lung transplant. The distance of maximum reach and sustainable endoscopic limit were measured. Transbronchial Needle Aspiration capability was assessed using the prototype 25G Aspiration Needle in segmental lymph nodes. Results In all evaluated lungs (n = 5), the thin convex probe EBUS demonstrated greater reach and a higher success rate, averaging 22.1 mm greater maximum reach and 10.3 mm further endoscopic visibility range than convex probe EBUS, and could assess selectively almost all segmental bronchi (98% right, 91% left), demonstrating nearly twice the accessibility as the convex probe EBUS (48% right, 47% left). The prototype successfully enabled cytologic assessment of subsegmental lymph nodes with adequate quality using the dedicated 25G Aspiration Needle. Conclusions Thin convex probe EBUS has greater accessibility to peripheral airways in human lungs and is capable of sampling segmental lymph nodes using the Aspiration Needle. That will allow for more precise assessment of N1 nodes and, possibly, intrapulmonary lesions normally inaccessible to the conventional convex probe EBUS.
Sinchita Roychowdhuri - One of the best experts on this subject based on the ideXlab platform.
-
salvaging the supernatant next generation cytopathology for solid tumor mutation profiling
Modern Pathology, 2018Co-Authors: Sinchita Roychowdhuri, Meenakshi Mehrotra, Ana Maria Bolivar, Brette Hannigan, Stephanie Zalles, Wenrui Ye, Dzifa Y Duose, Rashmi Kanagalshamanna, Bedia A Barkoh, Russell BroaddusAbstract:With the expanding role of targeted therapy in patients with solid tumors, pathologists face the daunting task of having to maximize limited volume tissue obtained by fine Needle Aspiration for a variety of molecular tests. While most molecular studies on fine Needle Aspiration samples have been reported using cellular material, recent studies have shown that a substantial amount of DNA can be retrieved from the supernatant fluid of aspirate Needle rinses after cell pelleting for cytospin or cell block preparations. In routine clinical workflow, the supernatant is discarded; however this fluid may provide a complementary source of DNA for tumor mutational profiling. In this study, we evaluated the post-centrifuged supernatant from 25 malignant and 10 benign fine Needle Aspiration Needle rinses. The mean and median DNA yields from the supernatants were 445 ng and 176.4 ng (range, 15.1–2958 ng), respectively. Next generation sequencing using the Ion AmpliSeq Cancer Hotspot Panel v2 detected somatic mutations in all 25 malignant samples. No mutations were detected in any of the benign samples tested. When available, mutations detected in the supernatant fluid were compared to the next generation sequencing analysis performed on a prior or concurrent surgical specimen from the same patient and showed 100% concordance. In a subset of cases (n = 19) mutations in EGFR, KRAS, BRAF, PIK3CA, and NRAS were successfully confirmed by droplet digital PCR, providing an orthogonal platform for mutation analysis. In summary, in this study we show that post centrifuged supernatants from fine Needle Aspiration Needle rinses can provide a robust substrate for expanded mutation profiling by next generation sequencing, as well as hotspot mutation testing by droplet digital PCR. The ability to detect somatic mutations from otherwise discarded supernatant fluids offers the ability to triage and effectively utilize limited volume fine Needle Aspiration samples when multiple molecular tests are requested, without the need to re-biopsy for additional tissue samples.
-
salvaging the supernatant next generation cytopathology for solid tumor mutation profiling
Modern Pathology, 2018Co-Authors: Sinchita Roychowdhuri, Meenakshi Mehrotra, Ana Maria Bolivar, Brette Hannigan, Stephanie Zalles, Wenrui Ye, Dzifa Y Duose, Rashmi Kanagalshamanna, Bedia A Barkoh, Russell BroaddusAbstract:With the expanding role of targeted therapy in patients with solid tumors, pathologists face the daunting task of having to maximize limited volume tissue obtained by fine Needle Aspiration for a variety of molecular tests. While most molecular studies on fine Needle Aspiration samples have been reported using cellular material, recent studies have shown that a substantial amount of DNA can be retrieved from the supernatant fluid of aspirate Needle rinses after cell pelleting for cytospin or cell block preparations. In routine clinical workflow, the supernatant is discarded; however this fluid may provide a complementary source of DNA for tumor mutational profiling. In this study, we evaluated the post-centrifuged supernatant from 25 malignant and 10 benign fine Needle Aspiration Needle rinses. The mean and median DNA yields from the supernatants were 445 ng and 176.4 ng (range, 15.1–2958 ng), respectively. Next generation sequencing using the Ion AmpliSeq Cancer Hotspot Panel v2 detected somatic mutations in all 25 malignant samples. No mutations were detected in any of the benign samples tested. When available, mutations detected in the supernatant fluid were compared to the next generation sequencing analysis performed on a prior or concurrent surgical specimen from the same patient and showed 100% concordance. In a subset of cases (n = 19) mutations in EGFR, KRAS, BRAF, PIK3CA, and NRAS were successfully confirmed by droplet digital PCR, providing an orthogonal platform for mutation analysis. In summary, in this study we show that post centrifuged supernatants from fine Needle Aspiration Needle rinses can provide a robust substrate for expanded mutation profiling by next generation sequencing, as well as hotspot mutation testing by droplet digital PCR. The ability to detect somatic mutations from otherwise discarded supernatant fluids offers the ability to triage and effectively utilize limited volume fine Needle Aspiration samples when multiple molecular tests are requested, without the need to re-biopsy for additional tissue samples.
Alain Tremblay - One of the best experts on this subject based on the ideXlab platform.
-
flexible 19 gauge endobronchial ultrasound guided transbronchial Needle Aspiration Needle first experience
Respiration, 2017Co-Authors: Chung Chun Tyan, Priya Patel, Kasia Czarnecka, Daniela Gompelmann, Ralf Eberhardt, Marc Fortin, Paul Maceachern, Christopher A Hergott, Elaine Dumoulin, Alain TremblayAbstract:Background: Endobronchial ultrasound-guided transbronchial Needle Aspiration (EBUS-TBNA) is a well-established first-line invasive modality for mediastinal lymph
